Cyprotex PLC Launch of new laboratory in its US facility
March 31 2015 - 2:02AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
31 March 2015
Cyprotex PLC
("Cyprotex" or "the Company")
Cyprotex launches new high throughput laboratory in its US
facility
31(st) March, 2015; Cyprotex PLC (AIM:CRX), a specialist
ADME-Tox Contract Research Organisation (CRO), announced today the
launch of a new high throughput screening laboratory at its US
facility in Watertown near Boston. The laboratory replicates the
highly successful ADME screening laboratory in Cyprotex's UK
facility which has been developed in-house over the past 16 years
using the combined expertise of our skilled software engineers and
scientists. The unique platform allows Cyprotex to provide services
which generate high quality consistent data in a rapid and
cost-effective manner. All our customers, large and small, have
access to and can benefit from the services available in North
America.
The new facility houses state of the art automated liquid
handling instruments and LC-MS/MS analytical instruments as well as
a team of scientists and software engineers who are experienced in
the field of high throughput screening. The integration has been
led by our UK team who have been responsible for training staff and
managing the smooth transfer of existing procedures and cross
validation of the assays.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments:
"Expansion of our high throughput screening facility to the US has
always been a much desired part of our growth strategy plans. Our
unique software platform combined with state of the art automation
and bioanalytical capabilities make us one of the only contract
research facilities to be able to screen such large numbers of
compounds in such a wide range of assays with relative ease. The
medium and large Pharmaceutical companies who require high capacity
and high quality screening with short turnaround times are
realising the benefit of working with Cyprotex and as such the
number of strategic deals are increasing and are a key factor in
the growth of our business."
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20 7496
Cyprotex) 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors
About Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1000 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries. The Company's core capabilities include high quality in
vitro ADME screening services, mechanistic toxicology and high
content toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, predictive modelling
using PBPK and QSAR techniques, including Cloe(R) PK for in vivo PK
prediction, and a range of skin, ocular and endocrine disruption
services. For more information, see www.cyprotex.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALBLFXEXFFBBF
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024
